Tokyo, Dec. 20 -- UMIN Clinical Trials Registry (UMIN-CTR) received information related to the study (UMIN000060139) titled 'Comparative Effectiveness of Monoclonal Antibody Prophylaxis for Preventing Respiratory Syncytial Virus Infection in Infants: A Network Meta-Analysis' on Dec. 19.
Study Type:
Others,meta-analysis etc
Primary Sponsor:
Institute - Saga University
Condition:
Condition - Respiratory Syncytial Virus Infection
Classification by malignancy - Others
Genomic information - NO
Objective:
Narrative objectives1 - evaluate effectiveness and safety of monoclonal antibodies for preventing RSV infection
Basic objectives2 - Safety,Efficacy
Eligibility:
Age-lower limit - 1
days-old
Gender - Male and Female
Key inclusion criteria - (1) participants younger than 2 years of age; (2) evaluation of mAb prophylaxis for RSV, (3) with placebo or standard care in control group of RCT study design.
Key exclusion criteria - (1) included fewer than 10 participants in any study arm; (2) represented subgroup or post hoc analyses of previously published trials; or (3) studies focused on discontinued medicine such as motavizumab or suptavumab.
Target Size - 20000
Recruitment Status:
Recruitment status - Completed
Date of protocol fixation - 2025 Year 11 Month 27 Day
Date of IRB - 2025 Year 11 Month 27 Day
Anticipated trial start date - 2025 Year 11 Month 27 Day
Last follow-up date - 2025 Year 11 Month 27 Day
To know more, visit https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000068784
Disclaimer: Curated by HT Syndication.
